Findings

What do systematic reviews say?

28 questions · 28 findings · 2 reviews · Musculoskeletal

No studies found 5 · 17.9%GRADE not reported 0 · 0%Very low 7 · 25%Low 6 · 21.4%Moderate 10 · 35.7%High 0 · 0%

Serious adverse events · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Functional ability · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Low

Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Moderate

Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 131 participants
Moderate

Pulmonary arterial hypertension · people with systemic sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.7 [1.2, 2.3]
1 study · 156 participants
Moderate

Overall mortality · people with systemic sclerosis

Autologous myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 0.59 [0.24, 1.43]
1 study · 75 participants
Moderate

Event‐free survival · people with systemic sclerosis

Autologous myeloablative selective HSCT showed no clear difference in event‐free survival compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
HR 0.54 [0.23, 1.27]
1 study · 75 participants
Moderate